RECRUITING

Fibrostenotic Eosinophilic Esophagitis: Assessment Tools

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This protocol addresses a central hypothesis that fibrostenotic Eosinophilic Esophagitis (EoE) is characterized by abnormal esophageal structure and compliance compared to non fibrostenotic EoE and that distinctive cellular and molecular profiles predict the fibrostenotic phenotype. This study aims to define and assess the changes that occur in the structure and dynamics of the esophageal wall in pediatric Eosinophilic Esophagitis along with characterizing the histologic and molecular patterns in fibrostenotic EoE.

Official Title

Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools

Quick Facts

Study Start:2014-12
Study Completion:2024-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02453126

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:5 Years to 18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Scheduled to undergo a clinical upper endoscopy with biopsy
  1. * Known connective tissue disorder
  2. * Increased risk of bleeding
  3. * Inflammatory bowel disease, celiac disease, eosinophilic gastroenteritis, or any autoimmune disease
  4. * Other esophageal disease including known achalasia; history of caustic ingestion, esophageal surgery esophageal stricture for other known reason or other esophageal injury.
  5. * Use of oral or intravenous steroids in the preceding 60 days. (Swallowed topical fluticasone, budesonide, etc not included as exclusion criteria.)

Contacts and Locations

Study Contact

Cassandra Burger
CONTACT
720-777-5739
cassandra.burger@childrenscolorado.org

Principal Investigator

Calies Menard-Katcher, MD
PRINCIPAL_INVESTIGATOR
University of Colorado/Childrens Hospital Colorado

Study Locations (Sites)

Children's Hospital Colorado
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Calies Menard-Katcher, MD, PRINCIPAL_INVESTIGATOR, University of Colorado/Childrens Hospital Colorado

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-12
Study Completion Date2024-06

Study Record Updates

Study Start Date2014-12
Study Completion Date2024-06

Terms related to this study

Keywords Provided by Researchers

  • Eosinophilic Esophagitis
  • Esophageal Stricture

Additional Relevant MeSH Terms

  • Eosinophilic Esophagitis